3-ethyl-5-(N-(2-methoxyethyl)acetamido)-2-methylbenzo[d]thiazol-3-ium iodide | 1169757-01-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 3-ethyl-5-(N-(2-methoxyethyl)acetamido)-2-methylbenzo[d]thiazol-3-ium iodide
• 英文别名: N-(3-ethyl-2-methyl-1,3-benzothiazol-3-ium-5-yl)-N-(2-methoxyethyl)acetamide;iodide
• CAS: 1169757-01-0
• 化学式: C₁₅H₂₁N₂O₂S*I
• 分子量: 420.314
• InChiKey: SKWSPXFYMACMKJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.48
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  61.7
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DES KINASES DE TYPE CDC2 (CLK) ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2009085226A2

  公开（公告）日：2009-07-09

  Provided herein are compounds which are CDC2-Like Kinase (CLK) inhibiting compounds and methods of use thereof. The CLK-inhibiting compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, ocular disorders, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a Clk-inhibiting compound in combination with another therapeutic agent.